Introduction {#S1}
============

Immune suppression is closely related to the development of lymphatic metastases in melanoma patients. This is indicated by a reduction in the frequency of paracortical dendritic cells, activated T cells and activated endothelia in high endothelial venules in lymph nodes regional to melanoma ([@R1]-[@R4]). The sentinel node, the first lymph node to directly receive lymph from a primary melanoma and thus the node most influenced by the primary tumor is immune suppressed even before nodal metastases are detectable ([@R3]). In the absence of tumor cells in the sentinel node, immune-modulation is likely to be mediated by soluble immune suppressive factors released by melanoma cells and leukocytes at the primary tumor site ([@R4]). Interleukin-10 (IL-10) is a prime candidate for this role. Several studies have demonstrated elevated levels of IL-10 in serum from patients with later stages of melanoma ([@R5]-[@R7]). This T helper type 2 (Th2) cytokine impedes immune functions, including T cell proliferation, Th1 cytokine production, antigen presentation, and lymphokine-activated killer cell cytotoxicity. IL-10 is secreted by melanoma cells, including metastatic melanoma cells ([@R8]-[@R10]) as in other cancers and tumor infiltrating lymphocytes and has been reported to reduce immune surveillance in patients with advanced melanomas ([@R11]). Monocyte/macrophages, including tumor-associated macrophages, are a significant component of tumor-associated inflammatory infiltrates and having modulatory activities against the immune system can potentiate tumor progression ([@R12]). There is a need for further analysis of the tumor microenvironment and the extent that it is orchestrated by bioactive molecules from melanoma cells and their associated inflammatory cells.

Detection of gene expression at the mRNA level is critical for identification of cells that synthesize soluble and secretable proteins, such as cytokines. Immunohistochemistry can detect such proteins in cells that passively acquire them by endocytosis as well as in cells that synthesize them. The coexistence of specific mRNA and protein delineates cells that synthesize particular proteins ([@R13]). As previously described, the reverse transcriptase *in situ* polymerase chain reaction (RT *in situ* PCR) technique amplifies small amounts of specific mRNA sequences within cells ([@R14]-[@R17]). In this study, we evaluated expression of the gene for IL-10 (*IL10*) in surgically resected melanomas *in situ*, invasive primary melanomas, metastatic melanomas and melanocytic nevi using the RT *in situ* PCR technique. This report is part of a series of studies of immunosuppressive networks in the tumor environment and their correlation with tumor progression and susceptibility to metastases. Identification of the cells that express genes for immune modulatory cytokines contributes to our understanding of the molecular basis of biological responses within the microenvironment of primary and metastatic melanomas.

Materials and methods {#S2}
=====================

Archival tissues from melanomas and melanocytic nevi {#S3}
----------------------------------------------------

Forty-five formalin-fixed, paraffin-embedded tissue specimens were retrieved from the Surgical Pathology archives at UCLA (Los Angeles, CA) and the Klinikum Nürnberg Nord (Nürnberg, Germany) with Institutional Review Board permission from both institutions. Thirty-nine tissue blocks from melanomas and 6 from melanocytic nevi were evaluated: 21 from invasive primary melanomas, 6 from melanomas *in situ* and 12 from metastatic melanomas (9 lymph nodes \[7 sentinel nodes\], 1 skin, and 2 lung). Original slides from all tissues were reviewed (by AJC and/or PHW) and the diagnosis confirmed. Slides from primary melanomas were assessed for tumor invasiveness, growth pattern and the presence of radial growth phase and vertical growth phase. Primary melanomas showing both radial growth phase and vertical growth phase were categorized as vertical growth phase melanoma. Clark level of invasion ([@R18]) and the micrometer-measured thickness of invasive primary melanomas ([@R19]) were assessed.

Immunohistochemistry {#S4}
--------------------

Formalin-fixed, paraffin-embedded tissue sections (4μm thick) were deparaffinized in xylene and dehydrated in a series of graded ethanols. Endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 30 min. Epitope retrieval was performed by boiling in 0.01M citrate buffer, pH 6.0 for 30 min. Sections were incubated with a 1:200 polyclonal goat anti-human IL-10 antibody (R&D Systems, Minneapolis, MN) overnight at 4°C. The subsequent development of antibody-bridge labeling used the streptavidin-biotin-peroxidase method with biotinylated anti-goat antibodies (Dako, Glostrup, Denmark) and streptavidin horseradish peroxidase (Zymed Laboratories, South San Francisco, CA). The sections were then reacted with the chromogen aminoethyl carbazole (AEC; Zymed Laboratories) and counterstained with hematoxylin and mounted.

One step RT *in situ* PCR {#S5}
-------------------------

### Pretreatment {#S6}

Formalin-fixed, paraffin-embedded tissue sections were cut at 4μm thickness and placed on silane-coated glass slides, de-paraffinized and hydrated through xylene and a graded alcohol series. To determine the optimal duration of protease digestion, the slide-mounted tissue sections were digested with trypsin (0.2 or 0.4 mg/ml) in phosphate-buffered saline (PBS) for periods that ranged from 30 to 60 min at 37°C (Roche Diagnostics, Mannheim, Germany) and then treated with RNase-free DNase I (EPICENTRE Biotechnologies, Madison, WI) in PBS at 37°C overnight.

### Oligonucleotide primer {#S7}

The oligonucleotide primer sequences for IL-10 mRNA ([@R20]) are shown as follows: the forward primer, 5′-AGCTCAGCACTGCTCTGTTG-3′ and the reverse primer, 5′-GCATTCTTCACCTGCTCCAC-3′. The RT-PCR cDNA product was 428 bp.

### One step RT-PCR {#S8}

The one step RT *in situ* PCR approach used a technique based on descriptions in recent articles ([@R17], [@R21], [@R22]). The Gene Amp EZ r*Tth* (recombinant *Thermus thermophilus*) RNA PCR Kit (Applied Biosystems, Foster City, CA) was employed. Each slide was loaded with the following mixture: 15μl of 5× EZ r*Tth* buffer, 9μl of Mn(OAc)~2~, 2.4μl each of dATP/dCTT/dGTT/dTTP, 3μl of r*Tth* DNA polymerase (Applied Biosystems), 0.9μl digoxigenin-11-dUTP, 2.4μl of 2% bovine serum albumin (BSA), 1.3μl of RNase inhibitor (Roche), 2.3μl of each primer, and 30.7μl diethylpyrocarbonate (DEPC)-treated water. The slides were covered with HybriWell sealing covers (Research Products International, Mount Prospect, IL) and placed on the Gene Amp In Situ PCR System 1000 thermal cycler (PerkinElmer, Foster City, CA). cDNA syntheses were performed at 60°C for 30 min. After initial denaturation at 94°C for 3 min, the cDNA was amplified by 30 cycles of annealing at 55°C for 1 min and denaturation at 94°C for 30 sec. After RT-PCR, the slides were washed in 0.1× saline-sodium citrate with 2% BSA at 60°C for 15 min and rinsed in Tris-buffered saline (TBS) three times for 5 min.

### Immunodetection of RT-PCR products {#S9}

Following incubation with an alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche; 1:200) for 30 min, the digoxigenin-labeled RT-PCR products were visualized with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; Zymed Laboratories) for 3 to 15 min. The number of immune reactive cells was estimated semi quantitatively, as follows: grade 3+ (high), \>50% positive cells; grade 2+ (moderate), 10-50% positive cells; grade 1+ (low), \<10% positive cells; --, negative staining.

### Controls {#S10}

Negative control preparations were prepared by: 1) omission of the primer pair for IL-10; 2) omission of the r*Tth* DNA polymerase. Cytocentrifuge slides of Raji human B-lymphoblastic cells, expressing IL-10 ([@R23]) (kindly provided by Dr. Jian-Yu Rao, UCLA, Los Angeles, CA), served as a positive control.

Statistical Analysis {#S11}
--------------------

Differences in frequencies of positively staining cells in the different disease groups were analyzed by Fisher's exact test. Nonparametric data analysis for semi quantitative scores of IL-10 mRNA reactivity was performed using the Mann-Whitney *U* test if comparisons involved two groups and the Kruskal-Wallis test if comparisons involved three groups (melanoma *in situ*, invasive primary melanoma and metastatic melanoma). When significance was found, the Kruskal-Wallis test was followed *post hoc* by the Holm- Bonferroni test for multiple comparisons.

The distribution of cases of IL-10 mRNA-positive expression in melanocytic nevi, melanomas *in situ*, primary invasive melanomas and metastatic melanomas was evaluated using the Cochran-Armitage trend test. In primary melanomas (melanomas *in situ* and invasive primary melanomas), correlations between melanoma invasiveness (Clark level), micrometer-measured tumor thickness (Breslow thickness) and semi quantitative scores of IL-10 mRNA expression by tumor cells, lymphocytes and macrophages were evaluated by Spearman's rank correlation test. In evaluating Breslow thickness melanomas *in situ* (Clark level 1) were ranked lowest (considered as zero in the micrometer-measurement) because the micrometer-measurement is only applicable for invasive primary melanoma (Clark level 2-5). Partial and multiple correlation coefficients were calculated, correlating Clark level and the reactivity of IL-10 mRNA expression by tumor cells, lymphocytes and macrophages. The model fit was represented by adjusted coefficient of determination (*R^2^*) that determines the reliability of variables to explain variation in the dependent variable (Clark level).

A multiple logistic regression model was built to predict vertical growth phase in primary melanomas, using dummy variables for the IL-10 mRNA reactivity data. The model fit was represented by Nagelkerke *R^2^* that determines the reliability of variables in the logistic regression model to explain the phenomenon (vertical growth phase) ([@R24]).

Statistical significance was considered to be *P*\<0.05. Two-tailed *P*-values are quoted throughout. All data were analyzed using the statistical package R: A language and environment for statistical computing (<http://www.R-project.org/>) ([@R25]).

Results {#S12}
=======

IL-10 expression in tumor cells {#S13}
-------------------------------

A positive reaction was indicated by the presence of specific RT-PCR purple to blue-colored products detectable by microscopic examination. [Table 1](#T1){ref-type="table"} summarizes IL-10 mRNA and protein expression by lesional cells of nevi and primary and metastatic melanomas. Melanocytic nevi (0/6) expressed neither IL-10 mRNA ([Figure 1A](#F1){ref-type="fig"}) nor IL-10 protein. IL-10 mRNA was detected in 30/39 melanomas (77%) and IL-10 protein in 30/36 (83%) melanomas. IL-10 mRNA and protein were present in epidermis-associated tumor cells of 2/6 melanomas *in situ* (33%) (The example of melanoma *in situ* shown in [Figure 1B](#F1){ref-type="fig"} is negative for IL-10 mRNA and protein). IL-10 mRNA was detected in 17/21 invasive primary melanomas (81%) ([Figure 1C](#F1){ref-type="fig"}) and IL-10 protein in 17/19 invasive primary melanomas (89%). IL-10 mRNA was present in 11/12 metastatic melanomas (92%) ([Figure 1D](#F1){ref-type="fig"}) and IL-10 protein in 11/11 metastatic melanomas (100%). RT-PCR amplified IL-10 mRNA and immunohistochemistry detected protein were located most concentrated in the cytoplasm of tumor cells, though there was minor nuclear staining for mRNA. The Fisher exact test revealed significant differences in IL-10 mRNA and protein expression between melanocytic nevi and primary melanomas (*P*\<0.01) and between melanocytic nevi and metastatic melanomas (*P*\<0.0001). IL-10 mRNA and protein were detected at a significantly higher frequency in the lesional cells of invasive primary melanomas (Fisher's exact test-*P*\<0.05) and metastatic melanomas (Fisher's exact test-*P*\<0.01) relative to melanomas *in situ* ([Table 1](#T1){ref-type="table"}). Reactivity scores were recorded in an attempt to quantify the amount of IL-10 mRNA present in melanoma cells at different stages of tumor evolution. These reactivity scores showed statistically significant differences between melanomas *in situ*, invasive melanomas and metastatic melanomas (Kruskal-Wallis test-*P* \<0.01). A *post hoc* Holm-Bonferroni test revealed that IL-10 mRNA reactivity in invasive melanomas and metastatic melanomas was significantly higher than that in melanomas *in situ* (*P*\<0.01, *P*\<0.05, respectively) ([Figure 2A](#F2){ref-type="fig"}).

Neither IL-10 mRNA expression nor IL-10 protein expression was observed in normal melanocytes in the epidermis adjacent to melanomas (data not shown). All negative controls, including omission of the primers and omission of the *Tth* DNA polymerase, gave negative results.

IL-10 expression by macrophages and lymphocytes {#S14}
-----------------------------------------------

IL-10 mRNA ([Figure 3A](#F3){ref-type="fig"}) and protein ([Figure 3B](#F3){ref-type="fig"}) were detected in macrophages and lymphocytes in tissues adjacent to primary melanomas. Many macrophages (including melanophages) located close to a melanoma expressed both IL-10 mRNA and protein and levels of expression were often high. IL-10 protein expression by lymphocytes was more limited, occurring in a few lymphocytes at less intense levels than observed in macrophages. IL-10 mRNA expression by macrophages and lymphocytes was similarly frequent in infiltrates adjacent to vertical and radial growth phase melanoma ([Figure 2B](#F2){ref-type="fig"}).

In a melanoma metastatic to the lung, IL-10 mRNA expression was observed in melanoma cells ([Figure 3C and D](#F3){ref-type="fig"}) and tumor-adjacent alveolar macrophages ([Figure 3E](#F3){ref-type="fig"}).

Correlation between tumor invasiveness and IL-10 mRNA expression {#S15}
----------------------------------------------------------------

The Cochran-Armitage trend test showed that IL-10 mRNA reactivity, absent in melanocytic nevi, occurred at progressively increasing frequency in melanomas *in situ*, invasive primary melanomas and metastatic melanomas (*P\<*0.0001). In 27 primary melanomas, including melanomas *in situ* and invasive melanomas, Spearman correlation analysis ([Table 2](#T2){ref-type="table"}) showed a very significant direct correlation between IL-10 mRNA expression by tumor cells and increasing Clark level of invasion (*r*=0.53) and increasing Breslow thickness (*r*=0.41). There was a significant correlation between expression of IL-10 mRNA in tumor-adjacent lymphocytes and expression in tumor-adjacent macrophages (*r*=0.47).

In a model where Clark level was a dependent variable, the multiple correlation coefficient (*R*) was 0.68, and the adjusted *R^2^* was 0.40. By removing the effects of the reactivity of macrophages and lymphocytes, the partial correlation coefficient between Clark level and the reactivity of tumor cells was 0.62, slightly higher than the corresponding Spearman's correlation coefficient (*r*=0.53). By removing the effects of Clark level and the reactivity of tumor cells, the partial correlation coefficient between reactivity of lymphocytes and macrophages was 0.52. The partial correlation coefficients between the reactivity of macrophages and tumor cells or Clark level were significant, while the corresponding Spearman's correlation coefficients were not significant. By removing the effects of reactivity of tumor cells and of lymphocytes, the reactivity of macrophages inversely correlated to Clark level (*r*=−0.49). By removing the effects of Clark level and the reactivity of lymphocytes, the reactivity of tumor cells correlated to that of macrophages (*r*=0.51).

When we compared the IL-10 mRNA reactivity scores of radial growth phase and vertical growth phase melanoma, scores were significantly higher in vertical growth phase melanoma (*P*\<0.01) ([Figure 2B](#F2){ref-type="fig"}). To predict that a melanoma is in vertical growth phase, a multiple logistic regression model was built using dummy variables for the expression of IL-10 mRNA ([Table 3](#T3){ref-type="table"}). Nagelkerke *R^2^* for the logistic regression model was 0.52 (*P*\<0.05), indicating a good fit of the data to the model. In this model, moderate to high IL-10 mRNA expression by tumor cells was confirmed to be significantly associated with the vertical growth phase of melanoma (*P*\<0.05).

Discussion {#S16}
==========

Melanomas evolve through sequential steps as the capacities for local invasion and metastatic competence evolve. During the radial growth phase, melanoma cells proliferate within the epidermis with, at most, limited non-tumorigenic penetration of the dermis by single cells or very small groups of cells (invasive radial growth phase) in the later stages of radial growth phase evolution ([@R26], [@R27]). Radial growth phase melanoma treated by complete surgical excision has a very low risk of local regrowth or metastasis. When melanoma cells acquire the capacity to form a tumor (tumorigenicity) and infiltrate more extensively into the dermis and subcutaneous tissues, the melanoma is considered as being in the vertical growth phase and having acquired the capacity to metastasize ([@R27]-[@R29]). In line with a recent report ([@R30]), our results indicate that IL-10 production by melanoma cells increases as melanomas progress through these evolutionary steps, paralleling the development of metastatic competence. This alteration in the capacity to generate and secrete IL-10 is associated with the increasing prognostic implications of transition from radial to vertical growth phase and the developing risk of regional and visceral metastases. In primary melanomas, the presence of detectable IL-10 mRNA in tumor cells correlated with increasing Clark level, an index of progression of the vertical growth phase to involvement of the deeper dermis and subcutis and a direct correlate of increasing metastatic potential. The frequency of melanoma cells with detectable IL-10 mRNA also increased with increasing Breslow thickness, but the correlation was less strong than with Clark level. These data indicate the frequency of melanoma cells that express detectable IL-10 and do not indicate the actual amounts of IL-10 expressed by tumor cells. The mechanisms that drive IL-10 over expression in melanoma cells are not fully known. Over expression of IL-10 may be due to chromosomal aberrations that are known to occur in melanomas. A gain of chromosome 1q (on which the human IL-10 gene is cytogenetically located) has been reported in melanomas ([@R31]-[@R33]) and could induce IL-10 overexpression.

Melanoma-derived IL-10 may suppress the differentiation and function of dendritic cells ([@R10]) and levels of IL-10 are reportedly higher in sentinel nodes than in non-sentinel nodes in patients with residual primary melanoma or metastatic melanoma in the sentinel node ([@R34], [@R35]). Thus the suppression of immunological functions in melanoma-draining sentinel node may be down-regulated by immunosuppressive cytokines derived from melanoma (and other) cells located outside the lymph node. IL-10 produced by melanoma cells, acting as an autocrine growth factor, can auto-stimulate proliferation of the cells that produce it leading to even higher levels of IL-10 ([@R36]). In the present study, IL-10 expression by melanoma cells correlated with the extent of primary tumor invasion. Expression of IL-10 mRNA was moderate to high in the tumor cells of vertical growth phase melanoma and metastatic melanoma. This suggests that IL-10 production by melanoma cells may be related to the primary tumor's capacity to proliferate, expand and invade adjacent tissues and acquire critical competence for metastasis. IL-10 expression is more significantly correlated to increasing invasion of the deeper layers of the skin (Clark level), than to micrometer-measured tumor thickness (Breslow). This suggests that once the cellular characteristics of the vertical growth phase are established, increasing tumor cell numbers, as evidenced by increasing Breslow thickness (a surrogate for tumor volume), does not change the relative frequency of IL-10-expressing tumor cells. It is also noteworthy that individual tumor cells of some melanomas *in situ* may produce IL-10, suggesting that even before transgression of the basement membrane, melanoma cells may generate releasable molecules capable of inducing immune suppression. This is in line with the view that melanomas can modulate the local microenvironment and that such modulation is part of the mechanisms that facilitate tumor growth and invasion.

Melanocytic nevi are benign, focal proliferations of melanocyte-derived cells that can remain stable for many years, but may infrequently act as precursors of melanoma. In this study, IL-10 expression was absent from nevus cells and normal melanocytes in sections of ostensibly normal skin adjacent to nevi and melanomas. IL-10 can be detected in cultured melanocytes *in vitro*, but the level of IL-10 expression in such cultures is extremely low compared to that in melanomas ([@R37]).

Peritumoral inflammatory cells play a key role in the promotion or subversion of adaptive immunity and in inflammatory circuits that may promote tumor growth and progression ([@R38]-[@R40]). Tumor-associated macrophages have dual roles in relation to neoplasms. While tumor-associated macrophages can kill neoplastic cells, following activation by IL-2, interferon and IL-12, tumor-associated macrophages "educated" by the tumor microenvironment can produce potent angiogenic and lymphangiogenic growth factors, as well as cytokines and protease mediators that can promote tumor progression and metastasis ([@R12], [@R39], [@R41], [@R42]). This study shows that IL-10 is produced by tumor-associated macrophages and tumor-related lymphocytes associated with early stages of tumor evolution, including melanoma *in situ*. Macrophages associated with thin primary melanomas contained more IL-10 mRNA than macrophages associated with deeper and thicker primary melanomas, suggesting that peak generation of IL-10 by tumor-associated macrophages may be selectively associated with the earliest phases of tumor invasion. The presence of detectable IL-10 mRNA in macrophages correlated directly with detectable IL-10 mRNA in melanoma cells, making it likely that both types of cells contribute to IL-10-induced immune suppression. We also demonstrated IL-10 production by alveolar macrophages located close to metastatic melanoma in the lung. Such macrophages located close to a metastasis along with the actual metastatic tumor cells could also induce local immune suppression. We cannot, however, entirely exclude the possibility that the highly sensitive RT *in situ* PCR technique may augment acquired nucleotides in the cytoplasm of macrophages which have phagocytosed melanoma cell components (including IL-10 mRNA and protein).

Immunoregulatory T cells, CD4+CD25+ T regulatory cells are capable of suppressing anti-tumor immunity ([@R30], [@R43]), and this class of cells derived from lymph nodes that contain metastatic melanoma can produce IL-10 upon allogeneic stimulation, but T helper cells have also been reported to secrete IL-10 ([@R44]). Immunosuppressive monocytes/macrophages having the same characteristics as tumor-associated macrophages can be induced by the influence of T regulatory cells ([@R45]). In this study, the presence of detectable IL-10 mRNA in macrophages correlated directly with detectable IL-10 mRNA in lymphocytes. Further investigation will investigate whether these IL-10-secreting peritumoral lymphocytes are T regulatory cells. Thus, through elaboration of immunosuppressive cytokines such as IL-10, macrophages and lymphocytes contribute to the immune suppression that impedes development of effective anti-tumor immune responses. They may induce localized and specific immune paralysis at both primary and metastatic sites, facilitating growth of primary and metastatic melanoma. Further studies are needed to elucidate the specific mechanisms of cross talk between different cell types within the tumor and surrounding inflammatory cells.

In summary, IL-10 production by tumor cells increases as primary melanomas progress with important prognostic implications for the transition from melanoma *in situ* to invasive melanoma and metastatic melanoma. Macrophages and lymphocytes infiltrating around primary and metastatic melanoma may also contribute to immune suppression. The release of immunosuppressive factors from melanoma cells, tumor-associated macrophages and lymphocytes appear to contribute to localized and specific immune down-regulation at both primary and metastatic sites. The findings are consistent with the proposal that IL-10, acting with other cytokines, induces immune down-regulation that may render sentinel nodes susceptible to the development of metastases. Understanding the interaction between tumor cells and the immune network in the immune suppression of anti-tumor immunity will help to provide insights that will permit the introduction of future novel therapeutic approaches to the management of patients with melanoma.
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![**(a)** Melanocytic nevus is negative for IL-10 mRNA by the RT *in situ* PCR technique. **(b)** Melanoma *in situ*. The RT *in situ* PCR technique shows that in some areas, melanoma cells express IL-10. Chromogen: NBT/BCIP. **(c)** Primary invasive melanoma. The RT *in situ* PCR shows that melanoma cells express IL-10 mRNA. Chromogen: NBT/BCIP. **(d)** Metastatic melanoma. The RT *in situ* PCR shows that IL-10 mRNA is most concentrated in the cytoplasm of and the nucleus contains less reaction product. Chromogen: NBT/BCIP.](nihms-252664-f0001){#F1}

###### 

**(a)** Reactivity scores of IL-10 mRNA expression in melanoma cells. As expressed by Box and Whisker plot, the central bar represents the median value, with 25th and 75th percentiles expressed by the box. There is a statistically significant difference in IL-10 between melanoma *in situ*, invasive melanoma and metastatic melanoma by the Kruskal-Wallis test (*P*=0.0057). The IL-10 mRNA reactivity scores in invasive melanoma and metastatic melanoma are significantly higher than in melanoma *in situ* (*P*=0.0086, 0.015, respectively; *post hoc* Holm Bonferroni test). **(b)** Box and Whisker plots. IL-10 mRNA expression by melanoma cells is higher in vertical growth phase than radial growth phase melanoma (*P*=0.0076). There were no significant differences in IL-10 mRNA reactivity of macrophages or lymphocytes between vertical growth phase and radial growth phase melanoma.
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![**(a)** IL-10 mRNA expression in lymphocyte and macrophage in primary melanoma. Macrophages including melanophages are strongly positive for IL-10 (dark blue color, marked by arrows). IL-10-positive lymphocytes are also present (blue color). Brown color is melanin. **(b)** Immunohistochemistry reveals that IL-10 is strongly expressed in some of macrophages including melanophages (red color, marked by arrows) and in scattered lymphocytes (red color, marked by asterisk). **(c, d)** In metastatic melanoma of the lung, IL-10 mRNA is diffusely expressed in tumor cells (blue color). **(e)** Alveolar macrophages near metastatic foci also express IL-10 mRNA in metastatic melanoma of the lung (blue color).](nihms-252664-f0004){#F3}

###### 

Expression of IL-10 mRNA and protein in tumor cells of primary and metastatic melanomas

  --------------------------------------------------------------------------------------
  Tumor                  IL-10 mRNA\                         IL-10 Protein\           
                         (RT *in situ* PCR)                  (immunohistochemistry)   
  ---------------------- -------------------- -------------- ------------------------ --
  Melanoma: total        30/39 (77%)                         30/36 (83%)              

   Primary melanoma      19/27 (70%)                         19/25 (76%)              

      *in situ*          2/6 (33%)            2/6 (33%)                               

    invasive             17/21 (81%)          17/19 (89%)                             

   Metastatic melanoma   11/12 (92%)          11/11 (100%)                            

  Melanocytic nevi       0/6 (0%)             0/6 (0%)                                
  --------------------------------------------------------------------------------------

*P* \<0.05

*P* \<0.01

###### 

IL-10 mRNA reactivity in tumor cells, macrophages and lymphocytes correlated with stage of melanoma evolution (melanoma *in situ* and invasive melanoma). *R* =0.68 (dependent variable: Clark level, *P* =0.0016). Adjusted *R ^2^* =0.40. Melanoma *in situ* was ranked lowest in consideration of Breslow thickness.

                      Clark level    melanoma cells   macrophages    lymphocytes
  ------------------- -------------- ---------------- -------------- -------------
  Breslow thickness   1              **0.41**\*       −0.07          0.27
                                                                     
  Clark level         1              **0.53**\*\*     −0.10          0.26
  melanoma cells      **0.62**\*\*   1                0.37           0.23
  macrophages         −**0.49**\*    **0.51**\*       1              **0.46**\*
  lymphocytes         0.38           −0.19            **0.52**\*\*   1

Bold: significant correlations (\*: *P* \<0.05, \*\*: *P* \<0.01)

Above the main diagonal: Spearman's correlation coefficients and *P* -values

Below the main diagonal: partial correlation coefficients and *P* -values

###### 

Multiple logistic regression model to predict characteristics of the vertical growth phase of melanoma (*P* =0.024, Nagelkerke *R ^2^* =0.52)

  Variables                                               Coefficient   S.E.   *P* -value
  ------------------------------------------------------- ------------- ------ ------------
  Constant                                                −1.46         1.17   0.21
                                                                               
  Low IL-10 mRNA expression by tumor cells                1.96          1.59   0.22
  Moderate to high IL-10 mRNA expression by tumor cells   4.40          1.72   0.011\*
  Low to moderate IL-10 mRNA expression by lymphocytes    1.46          1.81   0.42
  Low IL-10 mRNA expression by macrophages                −1.96         1.79   0.27
  Moderate to high IL-10 mRNA expression by macrophages   −3.89         2.39   0.10

S.E.: Standard Error
